Neuren Pharmaceuticals (ASX:NEU) received its one-third share of proceeds from Nasdaq-listed partner Acadia Pharmaceuticals' sale of the rare pediatric disease priority review voucher for $150 million in December 2024, according to a Friday filing with the Australian bourse.
The voucher was granted by the US Food and Drug Administration after the approval of Daybue for the treatment of Rett syndrome, the filing said.
Rett syndrome is a genetic disorder characterized by loss of mobility in the hands as development slows down.
The company is entitled to one-third of the proceeds under its license agreement with Acadia, per the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.